Clinical trials: Non-infectious Uveitis
Uveitis
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.
- Trial name
- EYEGUARD™-A (NCT01684345)
- Testing
- Dose 1 gevokizumab, Dose 2 gevokizumab
- Where
- 116 sites in United States, Argentina and 20 more
- Volunteers
- 200 people
- Sponsor
- XOMA (US) LLC
Anterior Uveitis
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- EGP-437-006 (NCT02517619)
- Testing
- Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis, Anterior Uveitis
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision.
- Conditions
- Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis
- Trial name
- NCT02764697
- Testing
- H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Tampa Bay Uveitis Center, LLC
Anterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
- Trial name
- NCT00333996
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Allergan
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Non-infectious Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant
This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide intravitreal implants for the management of subjects with non-infectious uveitis affecting the…
- Trial name
- NCT00456482
- Testing
- Fluocinolone Acetonide 0.59mg, Fluocinolone Acetonide 2.1mg
- Volunteers
- 239 people
- Sponsor
- Bausch & Lomb Incorporated
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Active Non-anterior Non-infectious Uveitis
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6…
- Trial name
- JAKUVEITE (NCT05651880)
- Testing
- Baricitinib 4 MG
- Where
- France
- Volunteers
- 33 people
- Sponsor
- University Hospital, Rouen
Uveitis, Biotherapy
Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis
RUBI, is the first prospective randomized, head to head study, comparing Adalimumab to either anakinra, or tocilizumab in refractory Non Infectious Uveitis (NIU).
- Trial name
- RUBI (NCT02929251)
- Testing
- Anakinra, Tocilizumab, Adalimumab
- Where
- 27 sites in France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Uveitis, Uveitis, Posterior
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- TYNI (NCT05486468)
- Testing
- Yutiq 0.18 MG Drug Implant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Texas Retina Associates
Uveitis
Abatacept in the Treatment of Uveitis
The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.
- Trial name
- NCT01279954
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Oregon Health and Science University
Non-infectious Anterior Uveitis
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
- Trial name
- NCT07136805
- Testing
- VVN461 Ophthalmic Solution 1.0%, 1.0% prednisolone acetate
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- VivaVision Biotech, Inc
Uveitis, Intermediate Uveitis
Sirolimus as Therapeutic Approach to Uveitis
The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential…
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- SAVE (NCT00908466)
- Testing
- Sirolimus (rapamycin)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Non-infectious Uveitis
Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS
prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and…
- Trial name
- CHRONOS (NCT05928754)
- Testing
- care strategy
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Uveitis
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
- Trial name
- EYEGUARD™-C (NCT01747538)
- Testing
- Dose 1 gevokizumab, Dose 2 gevokizumab
- Where
- 115 sites in United States, Argentina and 20 more
- Volunteers
- 281 people
- Sponsor
- XOMA (US) LLC
Uveitis
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at…
- Trial name
- LINNAEA (NCT04706741)
- Testing
- Izokibep, Prednisone/Prednisolone
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- ACELYRIN Inc.
Non Infectious Uveitis
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
- Trial name
- NCT03711929
- Testing
- DE-109 Intravitreal Injections, DE-109 Intravitreal Injections (Open Label)
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 145 people
- Sponsor
- Santen Inc.
Non-infectious Uveitis
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown…
- Trial name
- NCT03634475
- Testing
- PP-001
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Panoptes Pharma GmbH